MetaCap

Surrozen Inc. (SRZN)

NASDAQ: SRZNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

28.46-2.21 (-7.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SRZN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$596.40M
EPS (TTM)
-$41.94
52-week range
12.79 – 37.83
Day range
28.25 – 30.34
Volume / Avg
148.85K / 537.16K
Beta
—

52-week range

$12.79$37.83

SRZN stock today

Surrozen (SRZN) closed at $28.46 on Nov 20, down 7.21% (-$2.21), versus the S&P 500's 3.70% decline. Trading was light, with 148.85K shares changing hands, about 28% of the average daily volume. Shares are 24.8% below their 52-week high of $37.83, set on Sep 25, 2026 and 122.5% above the 52-week low of $12.79, in the middle of the past year's range.

SRZN is up 25.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 115.6%. Surrozen has posted a net loss over the last twelve months (EPS of -$41.94), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Surrozen

Company profile

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Craig C. Parker M.B.A.
Headquarters
South San Francisco, CA
Employees
44

Financial highlights

Full financials

In fiscal 2025, Surrozen generated $3.5 million in revenue, down 67.4% from fiscal 2024, its first annual decline since 2023. Surrozen reported a net loss of $242.0 million, compared with a loss of $63.6 million a year earlier. Operating margin was -1210.6%.

Surrozen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$3.48M$10.65M$0$12.50M$0
Growth-67.37%—-100.00%——
Net income$-242.03M$-63.56M$-43.04M$-36.00M$-54.65M
EPS (diluted)$-32.37$-21.67$-21.33$-15.56$-2.21

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$63.50+123.12%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $54.00High $80.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-4.75 vs $-1.32
Surprise
-259.85%

SRZN news

All SRZN news

Surrozen peers

Health Care sector
SRZN peer companies
CompanyPrice% ChgMarket capCompare
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs SRZN
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs SRZN
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs SRZN
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs SRZN
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs SRZN
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs SRZN
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs SRZN
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs SRZN

Indexes, lists and sector

Surrozen stock FAQ

What is Surrozen's stock price today?

SRZN last traded at $28.46 as of Nov 20, 4:00 PM EST, down 7.21% on the day. Prices are delayed at least 15 minutes.

Does Surrozen pay a dividend?

No. Surrozen does not currently pay a regular cash dividend.

Who is Surrozen's CEO?

Mr. Craig C. Parker M.B.A. is the chief executive officer of Surrozen Inc., which has about 44 employees.

Has SRZN ever split its stock?

Yes. The most recent SRZN stock split was a 1-for-15 split on Dec 14, 2023.

What is the SRZN 52-week high?

The 52-week high for SRZN is $37.83 and the 52-week low is $12.79. The stock is currently 24.8% below its high.

Compare SRZN